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Receptor-bindings (VACV) envelope proteins which are essential for cellular entry. However, their
speciﬁc roles during entry are unknown. We tested whether one or both of these proteins might serve as
receptor binding proteins (RBP). We found that a soluble, truncated form of L1, but not A28, bound to cell
surfaces independently of glycosaminoglycans (GAGs). Hence, VACV A28 is not likely to be a RBP and
functions after attachment during entry. Importantly, soluble L1 inhibited both binding and entry of VACV in
GAG-deﬁcient cells, suggesting that soluble L1 blocks entry at the binding step by competing with the virions
for non-GAG receptors on cells. In contrast, soluble A27, a VACV protein which attaches to GAGs but is non-
essential for virus entry, inhibited binding and entry of VACV in a GAG-dependent manner. To our
knowledge, this is the ﬁrst report of a VACV envelope protein that blocks virus binding and entry
independently of GAGs.
© 2008 Elsevier Inc. All rights reserved.Introduction
Vaccinia virus (VACV) is a complex, enveloped virus with an
∼189 kbp double stranded DNA genome. It is the prototypic member
of the Poxviridae family and was used successfully as a vaccine in the
worldwide effort to eradicate smallpox from the global human
population. Multiple infectious forms of VACV (Condit et al., 2006),
each with a different number of envelope layers, are produced during
infection, including the mature virion (MV/IMV) and the enveloped
virion (EV/EEV). The MV consists of a single membrane envelope and
is released from the infected host cell during lysis. A portion of MV
particles are also enwrapped by endosomal and/or trans-Golgi-
derived membranes and are subsequently exocytosed to become EV
particles. The EV has an additional outer membrane layer and thus
exhibits different proteins on its surface compared to the MV.
The majority of studies investigating the entry of VACV into host
cells have focused on the MV since they are more abundant and easier
to purify than EV particles (Ichihashi, 1996). Moreover, proteins on the
MV surface are important for entry of both forms of VACV (Law et al.,
2006; Senkevich et al., 2005). The envelope of the MV consists of
approximately twenty ﬁve integral or peripheral membrane proteinso).
l rights reserved.(Chung et al., 2006), at least sixteen of which have been implicated to
function in virus entry and/or fusion (A27, A17, H3, D8, L1, A28, H2,
A21, L5, G3, G9, A16, J5, F9, I2 and A26) (Brown et al., 2006; Chiu et al.,
2007; Ichihashi et al., 1994; Izmailyan et al., 2006; Kochan et al., 2007;
Lai et al., 1990, 1991; Lin et al., 2000; Nichols et al., 2008; Ojeda et al.,
2006a, 2006b; Senkevich and Moss, 2005; Senkevich et al., 2004;
Townsley et al., 2005a, 2005b). Of these, eight proteins (A28, H2, A21,
L5, G3, G9, A16, J5) form a conserved, multiprotein entry-fusion
complex (EFC) that is essential for the penetration of viral cores and
VACV-induced cell–cell fusion (Izmailyan et al., 2006; Ojeda et al.,
2006a, 2006b; Senkevich and Moss, 2005; Senkevich et al., 2005,
2004; Townsley et al, 2005a, 2005b). Monoclonal antibodies to L1,
another conserved MV envelope protein, diminish VACV-induced
cell–cell fusion at low pH (Ichihashi et al., 1994), and exhibit potent
virus-neutralizing activity in plaque reduction assays (Aldaz-Carroll et
al., 2005; Ichihashi, 1996; Wolffe et al., 1995). For this reason, L1 is a
key component of several subunit vaccine candidates currently in
development for protection against lethal orthopoxvirus diseases
(Fogg et al., 2004; Heraud et al., 2006; Hooper et al., 2004; Xiao et al.,
2007). Despite some recent progress, the speciﬁc functions of many of
these proteins during entry remain poorly deﬁned. It is currently
unclear if they function during or prior to membrane fusion, such as
attaching to cell surface molecules. In addition, the host cell receptor
(s) responsible for triggering internalization and/or membrane fusion
of VACV have not been identiﬁed.
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surface molecules. A27 and H3 bind to the cell surface glycosami-
noglycan (GAG) heparan sulfate (HSPG) (Chung et al., 1998; Lin et al.,
2000), D8 binds to chondroitin sulfate proteoglycan (CSPG) (Hsiao et
al., 1999), while A26 attaches to the extracellular matrix protein
laminin (Chiu et al., 2007). However, none of these proteins are solelyFig. 1. Recombinant VACV proteins produced in the baculovirus expression system. Schemati
top) of VACV A28 (A), F9 (C) and variola virus M1 (D). In C and D, the diagram of soluble L1 (bo
domains (TM), black lollipops represent sites for N-linked glycosylation potentially used in th
no homology with F9 (C), M points to the myristoylation site (D), S symbolizes conserved cys
used for afﬁnity puriﬁcation. Asterisks in (D) point to the two residues in variola virus M1 tha
recombinant A28 (A), F9 (C) or M1 (D) were puriﬁed by nickel chelate afﬁnity chromatograph
or transferred to a nitrocellulose membrane and then probed with a monoclonal antibody a
with arrows. The molecular weights of the markers are shown in kilodaltons. Note that recom
signal peptide was appended to the 5′ end of their ORFs (Aldaz-Carroll et al., 2005). (B) Re
soluble A28 or control A33 (Xiao et al., 2007) was resolved by SDS-PAGE under denaturing o
serum raised against VACV. Arrow points to the putative A33 dimer.essential for cell-binding or entry because other MV proteins can
complement adsorption (Chiu et al., 2007; Hsiao et al., 1999). On some
cell types, high concentrations of soluble GAGs do not inhibit VACV
infectivity (Carter et al., 2005). Moreover, mutant MV particles lacking
A26 still enter cells which do not express GAGs, even in the presence
of soluble laminin (Chiu et al., 2007), strongly suggesting the existencec diagrams depict the full length (top) or the truncated, recombinant form (second from
ttom)was also shown for comparison. Grey rectangles indicate putative transmembrane
e secreted recombinant proteins, dotted line in (C) depicts the region of L1 which shares
teines or intramolecular disulﬁde bonds (C and D) and H6 represent the six histidine tail
t are different in VACV L1 (R177 and I248 in M1 versus K177 and M248 in L1). Secreted,
y, separated by SDS-PAGE under reducing conditions and stained with silver nitrate (SS),
gainst the His-tag (WB). Migration positions of the recombinant proteins are indicated
binant L1 andM1 are not expected to be myristoylated since the sequence for a melittin
combinant A28 shares conformational epitopes with the authentic VACV A28. Puriﬁed
r native conditions, transferred to membranes and probed with a rabbit hyper-immune
Fig. 2. Antibodies to L1, A27 and A28 inhibit entry of VACV. Rabbits were immunized
with puriﬁed recombinant proteins L1, A27 or A28 to generate rabbit PAbs. VACV
vSIJC-20 was incubated for 1 h with increasing concentrations of the PAbs (R180 for
anti-L1, R194 for anti-A27 and R203 for anti-A28) or control antibody (preimmune).
The virus-antibody mixture was used to infect BSC-1 cells at an MOI of 0.5 PFU/cell.
β-galactosidase activity was assessed at 6 h p.i. as a measure of entry.
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laminin receptor(s) on the plasma membrane.
In this study, we hypothesized that L1 and/or the EFC component
A28 mediates attachment of VACV to cells by binding to non-GAG
receptor(s) on the plasmamembrane. Several criteria are often used to
assess whether a viral surface protein is a receptor-binding protein
(RBP): (i) antibodies to the viral protein inhibit virus entry, (ii) soluble
forms of the protein block virus entry at the adsorption step and (iii)
the soluble protein binds to cell surfaces. Hence, we produced soluble,
truncated forms of VACV L1 and A28 proteins using a baculovirus
system and tested for their abilities to interact with cell surface
molecules and to inhibit virus entry. Since a soluble, recombinant
form of A27 had been reported to bind to cell surfaces and block VACV
entry in a manner that is dependent on its GAG-binding domain
(Hsiao et al., 1998; Lai et al., 1990), we incorporated A27 in our study
for comparison. We found that soluble L1, but not A28, binds to cell
surfaces independently of GAGs. Therefore, A28 is not likely to be a
RBP. Interestingly, unlike soluble A27, soluble L1 blocks binding and
entry of VACV in GAG-deﬁcient cells. This suggests that VACV L1 may
function in entry as a RBP by engaging host receptor(s) which are
unique from GAGs.
Results
Puriﬁcation of soluble forms of VACV MV envelope proteins
To compare the roles of L1, A27 and A28 in the entry of VACV, we
employed a biochemical approach, testing soluble forms of each of the
MV proteins for their abilities to interact with cell surface components
and to perturb virus entry. The cloning and puriﬁcation of soluble
forms of L1 and A27 using the baculovirus expression system were
described previously (Aldaz-Carroll et al., 2005; Xiao et al., 2007). To
generate a soluble form of A28, we cloned the ectodomain of A28L
(residues 23–146) into baculovirus. We appended the sequences for
the melittin signal peptide and a six histidine tag to the N-terminus of
A28 (Fig. 1A). The protein was expressed and secreted from infected
insect cells and puriﬁed from the supernatant by nickel-chelate
afﬁnity chromatography. Puriﬁed A28 was analyzed using SDS-PAGE,
followed by silver staining or Western blotting (Fig. 1A). Under
reducing and denaturing conditions, soluble A28 migrated as four
major bands of 14–19 kDa. The three slowest migrating bands
represent N-glycosylated forms, since they were absent when the
protein sample was pretreated with PNGase F (data not shown).
To assess if recombinant A28was structurally similar to its genuine
counterpart from VACV, we used a rabbit hyper-immune serum
generated against VACV to probe for discontinuous epitopes in soluble
A28. The anti-VACV serum recognized soluble A28 when assessed by
Western blotting (Fig. 1B), indicating that at least a subset of the
antibodies in the rabbit serum detected A28-speciﬁc epitopes which
are common in both forms of A28. Importantly, these epitopes are
conformation-dependent, as the rabbit serum only recognized soluble
A28 when it was analyzed under native, but not under denaturing
conditions. In contrast, a different VACV protein, soluble A33 (Xiao et
al., 2007), was still revealed under denaturing conditions (Fig. 1B).
Hence, the recombinant A28 shares some conformational epitopes
with the authentic VACV A28.
Antibodies to L1, A27 and A28 inhibit virus entry
Viral structural proteins which are involved in entry into host cells,
such as RBPs or membrane fusion proteins for enveloped viruses, are
common targets of neutralizing antibodies. Therefore, we immunized
rabbits with puriﬁed A27 or A28 to obtain antisera for virus
neutralization studies. Anti-L1 rabbit polyclonal antibodies (PAbs)
were already available, as described previously (Aldaz-Carroll et al.,
2005). Although several investigators have reported the neutralizationcapability of antibodies to A27 (Czerny et al., 1994; Rodriguez et al.,
1985), these studies used the traditional plaque reduction neutraliza-
tion test (PRNT), which measures virion infectivity but not early
events such as virus entry. To determine if PAbs directed against L1,
A27 or A28 inhibit VACV infectivity at the stage of entry, we employed
a β-galactosidase entry assay. This assay utilizes a recombinant VACV
with the lacZ reporter gene regulated by a VACV dual early/late
promoter. During early events of VACV infection, viral encoded genes
regulated by early promoters are expressed shortly after release of the
cores into the cytoplasm, hence entry of the recombinant virus can be
determined by measuring β-galactosidase activity. Antibodies to L1,
A27 and A28 neutralized entry of VACV into BSC-1 cells in a dose-
dependent fashion (Fig. 2). Antibodies to A28 were especially effective
at neutralization, with an IC50 value of 400 ng/ml IgG. In contrast, the
IC50 values for the antibodies to L1 and A27 were 3.1 and 6.2 μg/ml IgG
respectively. These results suggest that L1, A27 and A28 all play a role
at an early step of VACV infection, and are in agreement with previous
studies which characterized the functions of these proteins in virus
entry using a variety of approaches (Chung et al., 1998; Hsiao et al.,
1998; Nelson et al., 2008; Rodriguez et al., 1987; Senkevich et al.,
2004; Wolffe et al., 1995).
Soluble L1 and A27, but not A28, block virus entry
When added exogenously during viral infection, soluble, recombi-
nant forms of viral RBP typically inhibit entry of mammalian viruses
by competing with the virion proteins for binding to the host
receptors (Chu et al., 2005; Jassal et al., 2001; Johnson et al., 1990).
We probed the ability of soluble L1, A27 and A28 to block virus entry
into several mammalian cell types: BSC-1, HeLa, B78H1 and Vero cells.
Our data indicate that soluble A28 did not signiﬁcantly affect VACV
entry into all cell types tested (Figs. 3A black bar, B, C and data not
shown). In contrast, 20 μM of soluble L1 and A27 blocked entry of
VACV into BSC-1 cells by 73% and 60% respectively (Fig. 3A, black bars).
Inhibition of lacZ expression by soluble L1 and A27 was detected as
early as 2 h p.i., suggesting that at least early gene expression of VACV
was affected (data not shown). The results for A27 recapitulate those
previously reported for recombinant A27 that was expressed in
bacteria (Hsiao et al., 1998). The blocking effect by the bacterial A27
was attributed to its interference with viral adsorption onto cell
surface HSPG (Hsiao et al., 1998). We also repeated these experiments
in HeLa human epithelial cells (Fig. 3B), B78H1 murine melanoma
cells (Fig. 3C), and Vero African green kidney monkey cells with
Fig. 3. Soluble L1 and A27, but not A28, block entry of VACV into several cell types. (A) Recombinant proteins inhibit lacZ expression of vSIJC-20 only if added to cells prior to virus
adsorption, indicating the blocking effect is at the stage of entry. A single concentration [20 μM] of soluble L1, M1, A28, A27, or F9 was either added to BSC-1 cells for 1 h at 4 °C prior to
virus binding and then cells were treated exactly as described in (B) below (black bars), added to virus-bound cells at time of transfer to 37 °C (grey bars), or added to virus-bound cells
at 30 min post transfer to 37 °C (white bars). β-galactosidase activity was subsequently measured at 6 h post transfer to 37 °C. (B, C and D) Increasing multiple concentrations of
recombinant L1, A27 or A28were incubatedwith HeLa (B) or B78H1 (C) cells seeded in 96-well plates for 1 h at 4 °C. VACV vSIJC-20was then added to the cells at anMOI of 2.5 PFU/cell
to allowadsorption. After 1 h at 4 °C, cells werewashed, transferred to 37 °C, and β-galactosidase activitywasmeasured at 6 h p.i. All data depicted are average values from at least two
independent experiments. (D) Soluble M1 and F9, which are homologous to L1, were also tested for their ability to block VACV entry using the same protocol.
371C.H. Foo et al. / Virology 385 (2009) 368–382similar results (data not shown). In all cases, the soluble proteins
inhibited entry of VACV in a dose-dependent manner. At a
concentration of 10 μM, soluble L1 inhibited VACV entry by 60% to
80% depending on the cell type tested. In contrast, the blocking effect
of soluble A27 was noticeably weaker in B78H1 cells (39% at 10 μM)than in BSC-1, HeLa or Vero cells (58%, 75%, and 62% respectively at
10 μM). This disparity could be due to differences in expression levels
of heparan sulfate moieties among the different cell types, or because
VACV can utilize alternative, non-HSPG molecules on the plasma
membrane of B78H1 cells for attachment.
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generated soluble forms of two homologs of L1 and tested them in the
entry assay. F9 is a MV protein that is essential for virus entry and
VACV-induced cell–cell fusion (Brown et al., 2006). F9 is structurally
homologous to L1, in that the two proteins have similar membrane
topology, share invariant cysteines, and have 25% sequence identity
(Fig. 1C) (Brown et al., 2006; Su et al., 2005). This sequence identity is
most pronounced in the ectodomains of the proteins, which are of
similar lengths. M1 is the variola virus ortholog of L1, sharing all but
one amino acid residue with L1 in its predicted ectodomain (Fig. 1D).
The puriﬁed F9 and M1 proteins were analyzed using SDS-PAGE,
followed by silver staining or Western blotting (Figs. 1C and D). Under
reducing and denaturing conditions, both proteins resolved as severalFig. 4. Soluble L1 and A27, but not A28, inhibit the penetration of VACV cores into cells. 20 μM
HeLa cells seeded on coverslips for 1 h at 4 °C. VACV vSIJC-20 was then added to the cells at an
to 37 °C and incubated for 2 h in the presence of cycloheximide. The cells were then ﬁxed wi
core rabbit polyclonal antibody. Intracellular cores were visualized at 1000× magniﬁcation (
confocal microscope using ﬂuorophore-conjugated goat-anti-rabbit antibodies (green in A).
optical sections perpendicular to the z-axis.closely migrating bands of 19–25 kDa, possibly representing differ-
entially glycosylated forms of the proteins. At 10 μM, soluble M1
blocked entry of VACV by approximately 72%, whereas soluble F9 did
not have any signiﬁcant effect, even though it was structurally
homologous to M1 and L1 (Fig. 3D). The results for M1 were not
surprising since the single amino acid difference between the two
proteins is conservative (Lys-177 in L1 compared to Arg-177 in M1).
To address the possibility that soluble L1 or A27 inhibits β-
galactosidase expression by affecting cellular functions such as protein
translation, we asked if soluble L1 or A27 could reduce enzymatic
activity when added to cells at, or shortly after the initiation of
penetration. Virions were preadsorbed to BSC-1 cells at 4 °C and then
soluble proteins were added either as soon as (Fig. 3A, grey bars) orof soluble L1, A27, A28 or culturemedium only (VACV only control) were incubated with
MOI of 50 PFU/cell to allow adsorption. After 1 h at 4 °C, cells werewashed, transferred
th 3% paraformaldehyde, permeabilized using 0.1% saponin and incubated with an anti-
A) and quantiﬁed (expressed as % of control without protein in B) under a ﬂuorescence
Cell nuclei were stained with TO-PRO®-3 iodide (red in A). The images represent single
373C.H. Foo et al. / Virology 385 (2009) 368–38230 min after (Fig. 3A, white bars) the incubation temperature was
shifted to 37 °C. Soluble L1, A27 and M1 signiﬁcantly inhibited β-
galactosidase expression only if added to cells prior to virus
adsorption (Fig. 3A, black bars). This indicates that blocking occurred
at an early stage of entry, perhaps during virus adsorption. Moreover,
the experiment shows that the blocking results were not due to non-
speciﬁc, broad cytotoxic effects caused by the proteins.
In addition to the β-galactosidase expression assay, we employed a
different, established approach to measure the entry of VACV. In this
penetration assay, intracellular VACV cores are visualized and
quantiﬁed using confocal immunoﬂuorescence microscopy (Vander-
plasschen et al., 1998). Consistent with our ﬁndings obtained using the
β-galactosidase assay, the addition of soluble L1 or A27 prior to virus
adsorption signiﬁcantly reduced the number of intracellular cores by
62% and 54% respectively (Fig. 4). Similarly, the presence of soluble
A28 did not alter the number of VACV cores (101% of control) that
were detected after virus entry into HeLa cells.
Soluble L1 and A27, but not A28, bind to surfaces of cells
It is possible that recombinant L1 inhibits virus entry by binding to
proteoglycans or to a speciﬁc cell surface receptor, thereby preventing
the authentic virion L1 from performing its task of receptor-binding
in entry. In addition, because soluble A28 did not block virus entryFig. 5. Soluble L1 and A27, but not A28, bind to surfaces of cells. Binding of proteins to cell
concentrations (A) or 10 μM (B) of soluble L1, A27, gD or A28 were incubated with BSC-1 cells
cells were washed, ﬁxed with 3% paraformaldehyde and then incubated with rabbit polyclon
enzymatically using HRP-conjugated anti-rabbit antibodies (A) or visualized under an epiﬂuo
nuclei were stained with DAPI (blue in B).(Figs. 3 and 4), we hypothesized that it would not bind to cell
surfaces, or at least not in a manner that is relevant for entry. To test
these hypotheses, we used a protein-cell binding assay (CELISA) to
determine if soluble L1 or A28 binds to cell surfaces (Connolly et al.,
2002). Herpes simplex virus (HSV) gD was used as a positive control
because it is a well-characterized viral RBP (Johnson et al., 1990;
Nicola et al., 1996). We found that soluble L1, A27 and HSV gD bound
to cell surfaces in a dose-dependent fashion (Fig. 5A). As predicted,
we detected no appreciable cell-binding by A28. The afﬁnity of
soluble A27 to cell surfaces appeared to be higher than those of
soluble L1 or HSV gD. Of note, the afﬁnity of soluble L1 seemed to be
in the sub-micromolar range. The cellular binding of A27 reached
saturation at a concentration of about 1 μM, while L1 and gD did not
achieve saturable binding at 10 μM. In general, the results for A27
agree with those from previous studies (Chung et al., 1998; Hsiao et
al., 1998). As a second approach, we employed indirect immuno-
ﬂuorescence microscopy to visualize binding of the proteins to cells
(Fig. 5B and Supplementary Fig. 1). In agreement with the CELISA
data, soluble A28 did not bind to cells, even at 10 μM. Here we
conclude that A28 is not likely to be a high-afﬁnity attachment factor
or a RBP, consistent with ﬁndings of other reports (Senkevich et al.,
2004; Turner et al., 2007). In contrast, soluble L1, A27 and control gD
bound to cell surfaces, with preferential association of soluble A27 at
cell–cell junctions.surfaces were assessed by CELISA (A) and indirect immunoﬂuorescence (B). Increasing
seeded in either 96-well plates (A) or on coverslips in 24-well plates (B). After 1 h at 4 °C,
al antibodies to the respective proteins. The amount of protein bound was quantitated
rescencemicroscope using ﬂuorescent-tagged goat-anti-rabbit antibodies (red in B). Cell
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Studies have shown that cellular HSPG is the binding partner of
A27 (Chung et al., 1998; Ho et al., 2005; Hsiao et al., 1998; Lin et al.,
2002). VACV L1may attach to proteoglycans akin to A27. Alternatively,
it may bind to important and distinct non-GAG receptor(s) that
activate subsequent steps of entry. Indeed, soluble L1 appear to have a
cell-binding pattern which is unlike that of soluble A27, with A27
localizing preferentially to cell–cell junctions when visualized by
microscopy (Fig. 5B). To determine if soluble L1 binds to proteoglycans
or non-proteoglycan receptors, we ﬁrst compared the binding of
soluble L1 to gro2C and sog9 cells, which are L cell mutants deﬁcient in
HSPG, or HSPG and CSPG synthesis respectively (Banﬁeld et al., 1995;
Gruenheid et al., 1993). Soluble HSV gC, which adheres to HSPG (Tal-
Singer et al., 1995), served as a control while soluble A27 was also
tested for comparison. Soluble L1 bound less well to gro2C cells than
parental L cells (1.6 fold decrease in binding at 10 μM) (Fig. 6A). In
addition, soluble L1 bound less well to sog9 cells than gro2C cells (1.8
fold decrease at 10 μM). Hence, our data suggest that both HSPG and
CSPG contribute to cell surface attachment of L1. However, there was
signiﬁcant residual binding of L1 and A27 to sog9 cells, in contrast toFig. 6. Soluble L1 and A27 bind to cell surfaces independently of glycosaminoglycans. (A, B and
a dose-dependent manner. Increasing concentrations of soluble L1 (A), A27 (B) or gC (C) were
HSPG and CSPG (sog9). After 1 h, cells were washed, ﬁxed, and the quantity of proteins attach
a CELISA format. (D) Soluble heparin only partially inhibits attachment of soluble L1 and A
chondroitin sulfate (open symbols) were preincubated with 3.75 μM soluble L1 (diamonds
soluble protein-GAGmix was then incubated at 4 °C with L cells. After 1 h, cells were washed
gC to cells. All data depicted in (D) were obtained from the same experiment but are presewhat was found for HSV gC (Fig. 6C). In fact, soluble L1 and A27 still
bound to the surface of these GAG-deﬁcient cells in a dose-dependent
manner (Figs. 6A and B), suggesting that L1 and A27 also bind to non-
GAG receptor(s) on cells. Similar results were reported for bacterial
A27 in another study using FACS analysis (Hsiao et al., 1999).
To pursue this hypothesis further, we next asked if pre-
incubation with soluble GAGs could eliminate cell surface binding
of soluble L1 or A27. If they bind to non-GAG receptors, these
proteins should still attach to cells even in the presence of high
concentrations of GAGs. Again, we used HSV gC as a control. Cell
surface attachment by L1 or A27 was partially blocked by incubation
with increasing quantities of soluble heparin (Fig. 6D, ﬁlled
diamonds and ﬁlled circles, respectively). However, complete
abrogation of cell surface binding was never achieved. 66% of the
binding of soluble L1 and 39% of the binding of A27 could not be
competed by heparin added at a high concentration (6.25 μg/ml).
Similar results were obtained in experiments using heparin at
concentrations as high as 25 μg/ml (data not shown). On the other
hand, binding of HSV gC to cells was virtually abolished by its
incubation with soluble heparin (Fig. 6D, ﬁlled triangles), in
agreement with published data (Tal-Singer et al., 1995). Pre-
incubation of L1 or A27 with soluble chondroitin sulfate had noC) Unlike soluble HSV gC, soluble L1 and A27 attach to surfaces of GAG-deﬁcient cells in
incubated at 4 °C with parental L (L cells) or mutant L cells deﬁcient in HSPG (gro2C), or
ed was probed using rabbit polyclonal antibodies to L1 (R180), A27 (R193) or gC (R47) in
27 to surfaces of cells. Increasing concentrations of soluble heparin (ﬁlled symbols) or
), 0.375 μM soluble A27 (circles) or 0.375 μM soluble gC (triangles) for 1 h at 4 °C. The
, ﬁxed, and CELISAwas performed as described above. Heparin abrogates attachment of
nted in separate ﬁgures for clarity.
375C.H. Foo et al. / Virology 385 (2009) 368–382effect on binding of the proteins to cells (Fig. 6D, open diamonds
and open circles respectively). When L1 was pre-incubated with a
combination of heparin and chondroitin sulfate, its binding was not
reduced further than it was with heparin alone (data not shown). In
sum, although L1 and A27 exhibit GAG-binding properties, they also
bind to cell surface molecules which are not proteoglycans.Fig. 7. Soluble L1, but not A27, blocks entry of VACV independently of cell surface proteoglyca
(B and E) or L1 (C and F) were incubated with parental L cells (open symbols or bars) or deriv
then added at anMOI of 2.5 PFU/cell (A–C) or 25 PFU/cell (D–F). The abilities of the proteins to
block cell-surface binding of VACV (D–F) were determined using an immunochemical assa
experiments.Soluble L1, but not A27, blocks virus entry independently of
glycosaminoglycans at the adsorption step
Our comparisons of L1 and A27 thus far suggest that both proteins
may function similarly in entry. Antibodies to L1 or A27 inhibit virus
entry, soluble forms of both proteins bind to cell surfacesns at the adsorption stage. Increasing concentrations of recombinant A28 (A and D), A27
ative GAG-deﬁcient sog9 cells (ﬁlled symbols or bars) for 1 h at 4 °C. VACV vSIJC-20 was
block entry of VACV (A–C) were then tested as described in Fig. 3 while their abilities to
y (virus-CELISA). All data depicted are average values from at least three independent
376 C.H. Foo et al. / Virology 385 (2009) 368–382independently of GAGs and both proteins also block entry of VACV.
Since it has been reported that the ability of A27 to block entry
depends on its GAG-binding domain (Ho et al., 2005; Hsiao et al.,
1998), it should not block VACV entry into cells devoid of
proteoglycans. On the other hand, if soluble L1 blocks entry by
sequestering non-GAG entry receptors, it should still inhibit virus
entry into GAG-deﬁcient cells. More importantly, this inhibition by
soluble L1 in GAG-deﬁcient cells should occur speciﬁcally at the step of
virus adsorption. In a virus-cell binding assay, soluble L1 should be
able to hinder the binding of virions to cell surfaces which are devoid
of GAGs. To test these possibilities, we compared the abilities of
soluble L1, A27 and A28 to block cell surface binding and entry of
VACV in parental L and mutant sog9 cells.
As was observed in BSC-1, HeLa and B78H1 cells (Figs. 3 and 4),
soluble A28 had no effect on the entry of VACV into L or sog9 cells
(Fig. 7A). Consistent with this observation, A28 also did not alter the
binding of VACV to these cells (Fig. 7D). As predicted, soluble A27
blocked VACV entry in sog9 cells to a much lesser extent than in L
cells (2.3 fold difference in efﬁcacy at 10 μM) (Fig. 7B). TheFig. 8. Neutralizing MAbs to L1 inhibit entry of VACV into cells independently of cell surface g
of MAbs which are neutralizers (VMC-3, VMC-5 and 7D11) or non-neutralizers (VMC-4 and V
assay was performed as described in Fig. 2. (C) Neutralizing MAbs to L1 do not block entry of
and VMC-3 (data not shown) were produced and tested for their ability to neutralize VACV e
fragments was normalized to reﬂect the equivalence of two moles of Fab subunit to one m
potential receptor-binding domains (Su et al., 2005). The cysteines involved in disulﬁde bon
sites are depicted. The neutralizing epitopes (red) of L1 were mapped to three discontinuou
epitope located near or at Asp-35 of loop 1 is recognized by MAb 2D5 (Ichihashi and Oie, 199
der Waals interactions with MAb 7D11-Fab (Su et al., 2007). The linear neutralizing epitope
helix and loop 3 (Aldaz-Carroll et al., 2005). A putative glycosylation site at Asn-27 of loopdifference in efﬁcacy observed between the two cell types was more
drastic when the inhibition of virus–cell binding was assessed (6.7
fold difference in efﬁcacy at 20 μM) (Fig. 7E). In fact, there was
minimal loss of VACV binding in sog9 cells when soluble A27 is
added.
Interestingly, soluble L1 blocked entry to a similar extent in both
cell types (Fig. 7C). 10 μM of soluble L1 blocked entry of VACV into L
and sog9 cells by 48% and 51% respectively. Importantly, this inhibition
of entry by soluble L1 is due to its ability to block the binding of VACV
to surfaces of cells (Fig. 7F), including cells devoid of proteoglycans.
The reduction in virus–cell binding also appeared to be more
efﬁcacious in the presence of proteoglycans. 20 μM of soluble L1
abrogated virus binding to L cells by 81% while the same amount of L1
reduced virus–cell association by 63% in sog9 cells.
Our data demonstrate that the ability of A27 to inhibit VACV entry
is primarily due to its binding to proteoglycans (Ho et al., 2005; Hsiao
et al., 1998). On the contrary, the ability of L1 to block cellular binding
and entry of VACV is independent of its GAG-binding property,
supporting the hypothesis that unlike the HSPG-binding VACV A27,lycosaminoglycans. VACV vSIJC-20 was incubated for 1 h with increasing concentrations
MC-35). Themixturewas then used to infect parental L (A) or sog9 cells (B) and the entry
VACV by crosslinking virions or steric hindrance. Fab fragments of Group 1 MAbs VMC-2
ntry in sog9 cells. IgG of VMC-4 served as negative control. The concentration of the Fab
ole of complete IgG unit. (D) Ribbon diagram of the crystal structure of L1 depicting
ding (green) and asparagine residues (blue) of the three putative N-linked glycosylation
s loops which are distal from the C-terminus transmembrane region. The neutralizing
6). Multiple residues of the discontinuous loops 1, 2 and 3 form hydrogen bonds or Van
recognized by MAbs VMC-3, 5, 6 and possibly, VMC-2 spanned residues 118–128 of α4′
1 is situated in the 7D11-Fab epitope.
Table 1
Properties of L1, A27, and A28, MV proteins which are involved in cell entry
L1 A27 A28
Blocking of entry by antibodies + + +
Binding by
soluble proteins
to various
targets
i. cells ++ ++ −
ii. heparina +/− + −
iii. GAG-deﬁcient
cells
+ + n/a
iv. cells in the
presence of
soluble GAGs
+ + n/a
Blocking of
entry by
soluble proteins
i. GAG-expressing
cells
++ ++ −
ii. GAG-deﬁcient
cells
++ +/− −
Blocking of
virus binding
by soluble
proteins
i. GAG-expressing
cells
++ ++ −
ii. GAG-deﬁcient
cells
++ − −
Entry phenotype of null-virus Defective in
entry and
VACV-induced
cell–cell fusionb
or assemblyc
Reduced
infectivity but
cell-binding
unaffectedd
Defective in
entry and
VACV-induced
cell–cell fusione
a As determined by afﬁnity chromatography using agarose beads conjugated to heparin
(Supplementary Fig. 2).
b Bisht et al. (2008).
c Ravanello and Hruby (1994).
d Due to the existence of other MV attachment proteins which can compensate for
the loss in HSPG-binding by A27 (e.g. D8 or L1) (Hsiao et al., 1999).
e Senkevich et al. (2004).
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Anti-L1 MAbs block virus entry independently of glycosaminoglycans
A panel of monoclonal antibodies (MAbs) to L1 have previously
been characterized (Aldaz-Carroll et al., 2005; Ichihashi, 1996; Wolffe
et al., 1995). Based on competitive-binding assays of peptides of L1, the
MAbs have been classiﬁed into two neutralizing groups and one non-
neutralizing group (Aldaz-Carroll et al., 2005). VMC-2, VMC-3 and
VMC-5 belong to the neutralizing Group 1 while VMC-4 and VMC-35,
which bind to discontinuous epitopes, are in non-neutralizing Group
2. 7D11, which also binds to non-linear epitopes (Su et al., 2007),
belongs to another group of neutralizing MAbs (Group 3). We wanted
to test whether the neutralizing activity of these antibodies is
contingent upon the presence of cell surface GAGs. If these neutraliz-
ing MAbs obstruct binding of VACV L1 to its cell surface non-GAG
receptor(s), but not to proteoglycans, their neutralization proﬁles
should be uniform in all L cell types, regardless of differences in
proteoglycan expression. As illustrated in Fig. 8, the neutralizing
activity of both groups of neutralizing MAbs virtually remained
unchanged in all L cell types assessed (compare Figs. 8A and B),
indicating that anti-L1 MAbs block virus entry via a mechanism that is
independent of cell surface proteoglycans.
Furthermore, we considered the possibilities that the neutraliz-
ing MAbs hinder entry of VACV either by forming non-functional L1
dimers on viral surfaces, or by aggregating virions together. We
therefore generated Fab fragments of the antibodies and examined
their ability to inhibit virus entry. The neutralization activities of
Fab antibodies from Group 1 (VMC-2 and VMC-3) were retained in
cells which do not express proteoglycans (Fig. 8C and data not
shown). The IC50 values for VMC-2 Fab and IgG were approximately
4 and 0.07 μg/ml respectively. The diminished neutralization
strength of the Fab antibodies is not surprising, since avidity is
lost once an antibody is converted from a divalent to a monovalent
form. In agreement with plaque reduction studies using 7D11-Fab
(Su et al., 2007), we conclude that MAbs do not neutralize virus by
causing inter and intra-virion crosslinking of L1. Rather, we suggest
virus entry is impeded by MAbs blocking binding of L1 to its non-
GAG molecular partner(s). These results, together with our other
observations, strongly suggest that unlike VACV A27, VACV L1 may
function in virus entry by binding to cellular receptor(s) which are
unique from proteoglycans.
Discussion
Role of L1 in the entry of VACV
Central to our current understanding of the entry of animal viruses
is the concept that it is a highly regulated, sequential process that is
triggered by signal(s) originating from the host cell (Weissenhorn et
al., 2007). One common trigger for entry of enveloped viruses is the
binding of a speciﬁc viral RBP to its host entry receptor. Upon binding,
the RBP undergoes conformational changes to effect subsequent steps
of the entry process, resulting in the fusion of the viral and host
membranes (Dimitrov, 2004; Reske et al., 2007; Weissenhorn et al.,
2007). Previous studies have shown that several MV envelope
proteins, including A27, H3, D8 and A26, attach to cell surface GAGs
or the extracellular matrix protein laminin, and that soluble forms of
A27, H3 and D8 block entry of VACV (Chiu et al., 2007; Chung et al.,
1998; Hsiao et al., 1999; Lin et al., 2000). These studies have
highlighted the importance of proteoglycans and laminin for the
attachment phase of the VACV entry process, but it is unclear whether
these interactions between the VACV envelope proteins and their
cognate receptors also serve as signals to activatemembrane fusion. In
any case, these MV proteins are non-essential for entry of VACV, andentry in GAG-deﬁcient cells cannot be completely blocked by soluble
laminin (Chiu et al., 2007), implying the presence of an alternative
receptor-ligand interaction that triggers VACV entry.
In this study, we found that soluble L1 bound to cell surfaces and
blocked virus entry at the adsorption step (summarized in Table 1).
Based on our binding curves, the afﬁnity of L1 with cell surfaces was in
the micromolar range and the binding did not saturate. The binding
afﬁnity between a viral RBP and its cognate receptor typically varies
depending on the abundance as well as the type of receptor molecules
on the particular cell type assessed. In some instances, such as HIV, the
afﬁnity between CD4 and gp120 is relatively high (nM range) and
binding of CD4 to cells is saturable (Lasky et al., 1987). For HSV gD, the
afﬁnity is low (μM range) and receptor abundance differs according to
the cell type (Fig. 5) (Spear, 2004; Willis et al., 1998). It is likely the
abundance of the cellular binding partner(s) of L1 is relatively low, at
least in the cell types we studied.
Our data suggest that a fraction of the cell surface association of L1
is due to proteoglycans, since cellular binding by L1 is partially
inhibited by soluble heparin and is reduced in GAG-deﬁcient cells.
Indeed, soluble L1 adhered to heparin directly (Supplementary Fig. 2),
although its afﬁnity to heparin seemed more modest than that of A27.
Nevertheless, a signiﬁcant portion of the cell surface binding by L1
cannot be accounted for by GAGs, indicating the presence of
alternative interactions between L1 and cell surface targets which
are non-GAG in nature. The bifunctional binding behavior of L1 is not
surprising since there are precedence from other viral RBPs (Bender et
al., 2005; Summerford et al., 1999; Vives et al., 2005). Importantly,
soluble L1 still blocked both entry and virion binding in GAG-deﬁcient
cells. This ﬁnding distinguishes L1 from A27, which exhibited GAG-
dependent characteristics in these assays. To our knowledge, this is
the ﬁrst report of a VACV envelope protein that blocks cellular binding
and entry independently of GAGs. Since the inhibition of entry by
soluble L1 occurs speciﬁcally at the step of virus adsorption, we
propose that VACV L1 functions in entry as a RBP by engaging a
cognate non-proteoglycan cellular receptor.
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assembly and morphogenesis (Ravanello and Hruby, 1994), a new
study recently characterized a conditional lethal L1 null mutant virus
which demonstrated a defect in entry and VACV-induced cell–cell
fusion, but not in assembly (Bisht et al., 2008). Our hypothesis
regarding L1 would be more consistent with the phenotype of the
mutant virus described in the later study by Bisht et al., (2008).
The crystallographic structure of the L1 ectodomain offers some
important insights into its function(s) (Su et al., 2005). The protein has
ﬁve α-helices packed against two double-stranded β-sheets (Fig. 8D).
It lacks structural features that are characteristic of known viral
membrane fusion proteins (Heinz and Allison, 2001; Skehel and
Wiley, 2000). Even though intermolecular interactions between L1
and components of the proposed entry-fusion complex have been
reported (Bisht et al., 2008), L1 is not required for the stability or
assembly of the complex and hence is not considered to be an integral
component of the complex (Bisht et al., 2008; Brown et al., 2006;
Senkevich et al., 2005). Furthermore, a recent study demonstrated
that the A17–A27 protein complex is sufﬁcient to induce cell–cell
fusion (Kochan et al., 2007). Thus, it is unlikely that L1 plays a direct
role in membrane fusion as a viral fusion protein during entry.
Interestingly, neutralizing epitopes of L1 are conﬁned to loops 1, 2
and 3 of its structure. These discontinuous loopsmay serve as domains
for interaction with the non-GAG receptor (Fig. 8D, red residues)
(Aldaz-Carroll et al., 2005; Ichihashi and Oie, 1996; Su et al., 2007). We
also showed that the virus neutralizing activity of anti-L1 MAbs does
not rely on the presence of proteoglycans. The nature of the L1
receptor and the domains on L1 which bind the receptor are subjects
for future investigations.
Role of A28 in the entry of VACV
It was proposed that components of the EFC, such as A28, are
unlikely to mediate attachment to cells since viruses lacking these
proteins bind to cell surfaces normally even though they cannot enter
cells (Izmailyan et al., 2006; Ojeda et al., 2006a, 2006b; Senkevich and
Moss, 2005; Senkevich et al., 2005, 2004; Townsley et al., 2005a,
2005b). However, functional redundancy in the cell surface binding
machinery of VACV may compensate for any potential loss in binding
by these mutant virions. Such a mechanismwas proposed for an A27-
null mutant virus that bound to cells as well as its parental virus strain
(Hsiao et al., 1999). Hence, experiments that assess the cell-surface
binding of puriﬁed, soluble whole EFCs or its individual components
are warranted to address this issue.
In this study, we found that the isolated A28 protein did not bind
to cell surfaces nor did it block VACV binding and entry
(summarized in Table 1). It is unlikely that the N-linked oligosac-
charides found on the recombinant A28 masked any inherent cell
binding motifs and interfered with our analyses, since recombinant
A28 which was deglycosylated with PNGase F also did not exhibit
any phenotype in our cell-binding or inhibition of entry assays
(Supplementary Fig. 3). Therefore, we conclude that A28 is unlikely
to be a RBP.
We found that PAbs to A28 inhibit entry of VACV, suggesting that
this protein functions at a post-receptor binding step such as
membrane fusion. Nelson et al., (2008) recently provided evidence
for a direct interaction between A28 and another component of the
EFC, H2 (Nelson et al., 2008). Their ﬁndings showed that this
interaction is dependent on a conserved sequence in H2 which shares
some similarity with fusion peptides from other viral membrane
fusion proteins. The authors postulated that A28 stabilizes the
putative fusion peptide in H2 during the prefusion state of the EFC
by concealing it from the aqueous environment. It may be possible
that PAbs to A28 neutralize virions by impeding the dissociation of
A28 from H2 when the EFC converts from its prefusion to fusogenic
intermediate state.Interestingly, while antibodies to L1 and A27 blocked virus entry as
much as 95% at the highest dose examined (100 μg/ml) (data not
shown), antibodies to A28 inhibited entry by no more than 60%, even
at high concentrations. Similar results were obtained for a different
anti-A28 PAb which we harvested from another A28-immunized
rabbit (data not shown). It is possible there is an alternative entry
mechanism or pathway that is resistant to anti-A28 antibodies.
Overall, our results corroborate key ﬁndings from a recent study
which also tested neutralization effects of different PAbs to A28
(Nelson et al., 2008).
Role of A27 in the entry of VACV
A27 is a well studied MV envelope protein and was one of the ﬁrst
identiﬁed cellular attachment proteins of VACV (Lai et al., 1990), even
though it is non-essential for virus entry (Hsiao et al., 1999). A
recombinant form of A27 which was expressed in bacteria blocked
binding and entry of VACV (Hsiao et al., 1998). The inhibition of entry
by A27 was dependent upon its N-terminal GAG-binding region, since
amutant A27 protein lacking this domain did not block entry (Hsiao et
al., 1998). Here, we found that recombinant A27 derived from insect
cells also blocked cellular binding and entry of VACV. The inhibitory
effects are primarily due to the A27-GAG interaction because they
were alleviated in GAG-deﬁcient cells. Nevertheless, we observed
some residual inhibition of entry by soluble A27 in these cells (Fig. 7B),
which could be due to high concentrations of soluble A27 disrupting
the non-covalent interactions between the virion A17 and A27
complex.
Our cell surface binding data for A27 also agree with those for a
bacterial form of A27 (Hsiao et al.,1998, 1999). Binding of soluble
baculovirus A27 to cells is saturable, suggesting speciﬁc interactions
with unique proteoglycans, such as heparan sulfates with speciﬁc
conﬁgurations. In addition, the afﬁnity of A27 to cell surfaces appeared
to be relatively high, with estimated Kd values varying within the
nanomolar range depending on the cell type analyzed.
In conclusion, our studies show that L1 fulﬁlls three criteria for a
viral RBP: (i) antibodies to L1 inhibit virus entry, (ii) soluble forms of
L1 block virus entry at the adsorption step and (iii) the L1 protein
binds to cell surfaces. We postulate that VACV L1 functions in entry by
engaging speciﬁc cell surface receptor(s) which are unique from
proteoglycans. Further investigations with L1 may facilitate the
discovery of novel poxvirus entry receptor(s) and improve our
understanding of how poxviruses trigger membrane fusion.
Materials and methods
Cells and viruses
BSC-1, HeLa, Vero, B78H1, murine ﬁbroblast parental L, mutant
gro2C and sog9 cells (Banﬁeld et al., 1995; Gruenheid et al., 1993) were
grown in Dulbecco's modiﬁed Eagle's medium (DMEM) containing
10% fetal calf serum (FCS). VACV vSIJC-20 (Western Reserve strain,
NC_006998) (S. N. Isaacs, unpublished data), a recombinant virus with
the lacZ gene under the control of the P7.5 early-late VACV promoter
was used in this study. For preparation of gradient-puriﬁed virus, BSC-
1 cells were infected at a MOI of 0.05 PFU/cell and incubated at 37 °C
until cytopathic effect was complete (3–4 days). The infected cell
cultures were homogenized on ice and its supernatant was clariﬁed of
cellular debris by centrifugation at 2000 ×g for 30 min at 4 °C. The
supernatant was then centrifuged at 25,000 ×g for 2 h at 4 °C and the
recovered pellet was resuspended in cold 10 mM Tris (pH 9.0),
sonicated and loaded atop a stepwise gradient of 60%, 36% and 15%
sucrose prepared in 10 mM Tris (pH 9.0). The step gradient was
centrifuged at 40,000 ×g for 4 h and banded virus was harvested via
side puncture of the tube. Collected virus was further concentrated by
pelleting through a cushion of 36% sucrose for 2 h at 5000 ×g. The
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sonicated, stored at −80 °C and titers were determined by plaque assay
with BSC-1 cells (Aldaz-Carroll et al., 2005). L cells and its mutant
derivatives were generous gifts from F. Tufaro and B. W. Banﬁeld.
VACV vSIJC-20 was kindly provided by S. N. Isaacs.
Antibodies and reagents
Rabbit polyclonal antibodies (PAbs) R193/R194 and R203/R204
were produced by immunizing rabbits with puriﬁed recombinant A27
and A28 proteins respectively, using procedures described previously
for raising PAbs against herpes simplex virus (HSV) glycoproteins
(Krummenacher et al., 1998). Preimmune antibody (control) was
harvested from a rabbit prior to immunization. Productions of rabbit
PAbs R180 and R47, raised against recombinant L1 and HSV-1 gC
respectively, were reported in previous studies (Aldaz-Carroll et al.,
2005; Eisenberg et al., 1987). Rabbit serum R8 was raised against HSV-
2 gD (Isola et al., 1989) while R236was raised against peptides derived
from the VACV A4 core protein (J. C. Whitbeck et al., in press).
Monoclonal antibodies (MAbs) VMC-2, VMC-3, VMC-4, VMC-5 and
VMC-35 were selected from a panel of monoclonal antibodies against
puriﬁed recombinant L1 (Aldaz-Carroll et al., 2005). MAb 7D11, raised
against VACV, was kindly provided by A. L. Schmaljohn (A. L.
Schmaljohn, J. W. Hooper and S. A. Harrison at the 1989 Annual
Meeting of the American Society for Virology) (Wolffe et al., 1995).
Immunoglobulin G (IgG) was puriﬁed from rabbit sera and murine
ascites ﬂuid with HiTrap protein G 1-ml columns (Amersham
Pharmacia Biotech) and dialyzed against phosphate buffered saline
(PBS). Fab fragments were generated from puriﬁed IgG using the
Immunopure® Fab Preparation Kit (Pierce). The anti-tetrahistidine
MAb was purchased from Qiagen Inc. Horseradish peroxidase (HRP)
conjugated anti-mouse and anti-rabbit secondary antibodies were
from Kirkegaard and Perry Laboratories. Anti-VACV rabbit hyper-
immune serumwas kindly provided by S. N. Isaacs (Isaacs et al., 1992).
Production and puriﬁcation of recombinant proteins
(i) Novel proteins — VACV A28, F9 and variola virus M1
The A28L and F9L open reading frames (ORF) were PCR ampliﬁed
from the respective cloned HindIII A and F fragments of the VACV
(Western Reserve strain, NC_006998) genome. The putative transmem-
brane domains of the full-length A28L (residues 4–26) and F9L ORFs
(residues 174–196) were excluded and only their ectodomains (residues
23–146 and 1–175 respectively) were expressed. For A28, the forward
primer used for PCR ampliﬁcation was: 5′-gcgggatccacaccaccaccaccac-
cacggttactcaatatatgaaaat-3′ (adds six histidine codons (underlined) to
the 5′ end of A28L ORF as well as a BamHI site (bold)) and the reverse
primer was 5′-gcggaattcaaagtacagattttagaaa-3′ (adds EcoRI (bold)).
Similarly for F9, the forward primer for PCR ampliﬁcation was: 5-
gctgatcacatggcggaaactaaagagttt-3′ (addsBclI site (bold)) and the reverse
PCR primer was 5′-gcgcgaattcagtgatgatggtgatgatgatcgtaatacgg-
caatcggttt-3′ (adds 6 histidine codons (underlined) to the 3′ end of F9L
ORF as well as an EcoRI site (bold)). The ﬁnal PCR products were either
digested with BamHI and EcoRI or BclI and EcoRI respectively, and
subsequently ligated into the baculovirus transfer plasmid, pVT-Bac
(Tessier et al., 1991) which was digested with the same set of restriction
enzymes. Therefore, the resulting recombinantplasmids containedORFs
consisting of the melittin signal sequence followed, in frame, either by
the six histidine codons and the ectodomain of A28 (codons 23–146), or
the F9 ectodomain (codons 1–175) and then six histidine codons.
A different cloning strategy was used for generating the pVT-Bac
plasmid which encodes recombinant variola virus M1. The ectodo-
mains of variola virus M1 (Variola major Bangladesh-1975 strain,
L22579) and VACV L1 (Western Reserve strain, NC_006998) differ in a
single amino acid residue (R177 in M1 versus K177 in L1). Hence, the
K177 codon in the truncated L1R ORF in a previously createdrecombinant pVT-Bac plasmid (Aldaz-Carroll et al., 2005) was
mutated to an arginine codon using the QuikChange site-directed
mutagenesis kit (Stratagene Cloning Systems) as described previously
(Connolly et al., 2002). Thus, similar to recombinant L1(185t), the
putative transmembrane domain of the full-lengthM1RORF (residues
186–204) was excluded and only the ectodomain (residues 1–185)
was expressed. The forward primer for QuikChange mutagenesis was:
5-ctcaaatagcacctagacaagttgctgg-3′ (substitutes into arginine codon
(bold)) and the reverse primer was 5′-ccagcaacttgtctaggtgctatttgag-3′
(substitutes into arginine codon (bold)). The resulting plasmid
contained ORF consisting of the melittin signal sequence followed,
in frame, by theM1 ectodomain (codons 1–185 with arginine codon at
position 177) and then six histidine codons.
The resulting pVT-Bac plasmids encoding recombinant A28, F9 and
M1 were co-transfected with baculovirus DNA (BaculoGold, BD-
Pharmingen) into Sf9 insect cells. After one week, recombinant
baculoviruses were harvested. The viruses were then plaque puriﬁed
and high titer stocks were prepared (Rux et al., 1998). The
recombinant proteins were secreted from infected insect cells and
puriﬁed from supernatants using nickel-chelate afﬁnity chromato-
graphy, as described previously (Rux et al., 1998). ForWestern blot and
silver stain analysis, puriﬁed recombinant proteins was separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) under native (0.1% SDS, no reducing agent, no boiling) or
reduced (boiled 10 min in 2.5% SDS, 350 mM β-mercaptoethanol)
conditions in precast Tris-glycine gels (Invitrogen). Following SDS-
PAGE, separated proteinswere either visualized by stainingwith silver
nitrate (Pharmacia) or were transferred to a nitrocellulose membrane
and then probed with antibodies and visualized by ECL (Amersham).
(ii) Previously characterized proteins — VACV L1, A27, A33 and
HSV glycoproteins
The production and puriﬁcation of recombinant VACV L1(185t), A27,
A33(58–185), HSV-1 gD(306t) and gC(457t) were described elsewhere
(Aldaz-Carroll et al., 2005; Rux et al., 2002, 1998; Xiao et al., 2007). The
puriﬁed soluble proteins were stored frozen at −80 °C in PBS.
Inhibition of virus entry by antibodies
Puriﬁed complete IgG or Fab fragments were serially diluted in
DMEM containing 5% heat-inactivated FCS and then mixed with an
equal volume of reporter virus VACV vSIJC-20. The virus-antibody
mixture was incubated for 1 h at 37 °C and then used to infect BSC-1,
parental L, gro2C or sog9 cells at a multiplicity of infection (MOI) of
0.5 PFU/cell in 96-well plates. After 6 h at 37 °C, β-galactosidase
expression was determined in a β-galactosidase entry assay as
described previously (Whitbeck et al., 1997). Cells were lysed by the
addition of an equal volume of PBS containing NP-40 (1.5% ﬁnal
concentration). Lysates were then mixed with the β-galactosidase
substrate (chlorophenol red-β-D-galactopyranoside; Roche) in a
separate 96-well plate and absorbance was measured at 570 nm in a
microtiter plate reader. Data were collected at 5-min intervals over
50 min and the amount of entry was calculated from the rate of
substrate conversion over time. After subtraction of background
values, net values fromwells where antibody was not added (control)
was set to 100% and virus entry was presented as a percent of control.
For experiments using Fab, the concentration of the Fab antibodies
were normalized to reﬂect the equivalence of two moles of Fab
subunit to one mole of complete IgG. Results presented are
representative of a series of at least two independent experiments.
Inhibition of virus entry by recombinant proteins
(i) β-galactosidase entry assay
Puriﬁed recombinant proteins (soluble L1, A27, A28, F9 or M1)
were serially diluted in DMEM containing 10% FCS and 30 mM HEPES
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well plates. After 1 h at 4 °C, an equal volume of reporter virus VACV
vSIJC-20 (diluted in DMEM-H) or control DMEM-H without virus was
added to the cells at a MOI of 2.5 PFU/cell and incubated for another
1 h at 4 °C to allow adsorption. Cells were washed with cold DMEM-H
to remove unbound virions, refed with warm media and then
transferred to 37 °C to allow synchronous penetration to proceed.
After 6 h at 37 °C, β-galactosidase expression as a measure of entry
was assessed as described above. In experiments designed to address
the possibility that soluble proteins inhibited lacZ expression by
affecting post-entry steps, the standard protocol described above was
also modiﬁed. Unlike the standard protocol, VACV vSIJC-20 (diluted in
DMEM-H) was ﬁrst allowed to adsorb to prechilled BSC-1 cell
monolayers at a MOI of 2.5 in 96-well plates. After 1 h at 4 °C, cells
were washed to remove unbound virions, refed with warmmedia and
then transferred to 37 °C. An equal volume of puriﬁed proteins [20 μM]
diluted in DMEM-H at RT were added to the cells either shortly before
transfer to 37 °C, or at 30 min post transfer to 37 °C. β-galactosidase
activity was measured at 6 h post transfer to 37 °C in both alternative
protocols. Unless otherwise stated, results presented are representa-
tive of a series of at least three independent experiments.
(ii) Immunoﬂuorescence microscopy of intracellular cores
20 μM of puriﬁed proteins (soluble L1, A27 or A28) was serially
diluted in DMEM-H and then added to prechilled HeLa cell mono-
layers grown on glass coverslips in 24-well plates. After 1 h at 4 °C,
VACV vSIJC-20 (diluted in DMEM-H) or control DMEM-H without
virus was added to the cells at a MOI of 50 PFU/cell and incubated for
another 1 h at 4 °C to allow adsorption. Cells were washed with cold
DMEM-H to remove unbound virions, refed using warm media with
100 μg/ml of cycloheximide and then transferred to 37 °C to allow
synchronous penetration to proceed. After 2 h at 37 °C, cells were
rinsed with ice-cold DMEM-H, ﬁxed with cold 3% paraformaldehyde
and washed again with PBS. Subsequent steps were performed at
room temperature. Cells were quenched with 50 mM NH4Cl for
10 min, permeabilized using 0.1% saponin dissolved in PBS and
incubated with blocking solution (10% goat serum in PBS) for 1 h. Cells
were incubated for 45 min with 0.25 μg/ml of anti-A4 rabbit antibody
IgG (R236) which was diluted in blocking solution. Following rinses
with PBS, cells were further incubated for 30 min with ﬂuorescent-
tagged anti-rabbit antibodies (GAR-488) and TO-PRO®-3 iodide
(Molecular Probes) diluted 1:1000 and 1:10,000 respectively in
blocking solution. After the ﬁnal washing step with PBS, cells were
rinsed once with distilled water. Coverslips were extracted from the
plates and mounted onto microscope slides in ProLong Antifade
mounting solution (Molecular Probes). Cells were observed under a
Nikon TE2000-U inverted microscope coupled to a PerkinElmer
confocal imaging system. A two-line argon krypton laser emitting at
488 and 568 nm was used. Images from multiple optical sections
perpendicular to the z-axis were captured for each ﬁeld at 1000×
magniﬁcation. The extent of viral penetration was determined by
counting all intracellular cores present in an average of 30 cells per
coverslip.
Binding of soluble proteins to the cell surface
(i) CELISA
We used a modiﬁcation of a cellular enzyme-linked immunosor-
bent assay (CELISA) (Connolly et al., 2002). Puriﬁed recombinant
proteins (soluble L1, A27, A28, gD or gC) were serially diluted in
DMEM-H and then added to prechilled, conﬂuent BSC-1 cell
monolayers grown in 96-well plates. After 1 h at 4 °C, cells were
rinsed with ice-cold DMEM-H, ﬁxed with cold 3% paraformaldehyde
and washed again with PBS supplemented with Ca++ and Mg++ (PBS+).
Subsequent steps were next performed at room temperature. Cells
were incubated for 1 h with 2.5 μg/ml of R180, R193, R204 antibodyIgGs or 1:2000 of R8 rabbit serawhichwere diluted in PBS+ containing
3% bovine serum albumin (PBS-B) (BSA Fraction V; Roche). Following
more rinses with PBS+, cells were further incubated for 45 min with
HRP-conjugated anti-rabbit antibodies diluted 1:1000 in PBS-B. After
the ﬁnal washing stepwith PBS+ containing 0.1% Tween-20, cells were
rinsed once with 20 mM citrate buffer, pH 4.5. 2,2′-Azinobis(3-
ethylbenzthiazolinesulfonic acid) (ABTS) peroxidase substrate (Moss,
Inc.) was added, and the absorbance at 405 nm was measured at
multiple time points with a micro titer plate reader. Unless otherwise
stated, results presented are representative of a series of at least three
independent experiments.
(ii) Immunoﬂuorescence microscopy
10 μM of puriﬁed proteins (soluble L1, A27, A28 or gD) diluted in
DMEM-H or control DMEM-H without protein was added to
prechilled, conﬂuent BSC-1 cell monolayers seeded on glass coverslips
in 24-well plates. After 1 h at 4 °C, cells were rinsed with ice-cold
DMEM-H, ﬁxed with cold 3% paraformaldehyde and washed again
with PBS+. Cells were quenched with 50 mM NH4Cl for 15 min and
incubated with blocking solution (10% goat serum in PBS+) overnight
at 4 °C. Subsequent steps were performed at room temperature. Cells
were incubated for 45 min with 5 μg/ml of R180, R193, R204 antibody
IgGs or 1:1000 of R8 rabbit sera which were diluted in blocking
solution. Following rinses with PBS+, cells were further incubated for
30 minwith ﬂuorophore-tagged anti-rabbit antibodies diluted 1:1000
in blocking solution. After the ﬁnal washing step with PBS+, cells were
rinsed once with distilled water. Coverslips were extracted from the
plates and mounted onto microscope slides in ProLong Antifade
mounting solution with DAPI (4′, 6′-diamidino-2-phenylindole)
(Molecular Probes). Cells were observed under a Nikon Eclipse E600
microscope and images were captured at 20× magniﬁcation.
Glycosaminoglycan inhibition studies
Serially diluted heparin or chondroitin sulfate A (Sigma) or both
were incubated with 3.75 μM of puriﬁed soluble L1 or 0.375 μM
of soluble A27 or gC in DMEM-H for 1 h at 4 °C. The protein-
glycosaminoglycan (GAG) mix was then added to prechilled,
conﬂuent cell monolayers cultured in 96-well plates. After another
1 h at 4 °C to allow binding of proteins to cells, cells were rinsed with
ice-cold DMEM-H, ﬁxed with cold 3% paraformaldehyde and
examined by CELISA for bound recombinant proteins.
Binding of VACV to the cell surface (virus-CELISA)
A cellular enzyme-linked immunosorbent assay (CELISA) was
adapted for the quantiﬁcation of cell-bound VACV (Connolly et al.,
2002). Recombinant proteins (soluble L1, A27 or A28) were serially
diluted in DMEM-H and then added to prechilled, conﬂuent parental L
or derivative sog9 cell monolayers grown in 96-well plates. After 1 h at
4 °C, an equal volume of VACV vSIJC-20 (diluted in DMEM-H) or control
DMEM-H without virus was added to the cells at a MOI of 25 PFU/cell
and incubated for another 1 h at 4 °C to allow adsorption. Cells were
rinsed with ice-cold DMEM-H, ﬁxed with cold 3% paraformaldehyde
andwashed againwith PBS+. Subsequent stepswere next performedat
room temperature. Cellswere incubated for 1 hwith 2.5 μg/ml of either
anti-A27 monoclonal antibody IgG (VMC-38) (J. C. Whitbeck et al.,
unpublished data) for wells added with soluble L1 or A28 proteins, or
anti-L1monoclonal antibody IgG (VMC-2) forwells addedwith soluble
A27 proteins. Antibodies were diluted in PBS-B. Following more rinses
with PBS+, cells were further incubated for 45 min with HRP-
conjugated anti-mouse antibodies diluted 1:1000 in PBS-B. After the
ﬁnal washing step with PBS+ containing 0.1% Tween-20, cells were
rinsed once with 20 mM citrate buffer, pH 4.5. ABTS peroxidase
substrate (Moss, Inc.) was added, and the absorbance at 405 nm was
quantiﬁed using a micro titer plate reader.
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